Skip to main content
OpenTrials
Completed

NCT Number: NCT05353725

Extracorporeal Membrane Oxygenation in Coronavirus Disease (COVID-19), Influenza and ARDS of Other Ethiologies

A comparison of clinical characteristics and outcomes of patients on extracorporeal membrane oxygenation (ECMO) in COVID-19, influenza and ARDS of other ethiologies

Completed

Looking for future studies?

Notify Me

Key information

Conditions

ARDS COVID-19 Coronaviridae Infections Coronavirus Infections Infections Influenza Influenza, Human Lung Diseases Nidovirales Infections Orthomyxoviridae Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

All ARDS patients on extracorporeal membrane oxygenation (ECMO) during January 1st 2016 and January 10th 2022 in University Medical Center Ljubljana were included and their clinical characteristics and outcomes were studied according to ARDS ethiology: COVID-19, influenza and other ethiologies.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient with acute respiratory distress syndrome (ARDS) on extracorporeal membrane oxygenation (ECMO)
  • 18 years or older

Exclusion criteria

  • Patient not eligible for ECMO treatment per institutional guidelines (terminal illness, palliative care)

Treatment and study plan

Primary outcomes

  1. 180-day survival

    Time frame: From day of ECMO-implant for every 24 hours until date of death or survival at 180 days

    180-day survival from ECMO implantation

Secondary outcomes

  1. Days on ECMO

    Time frame: From day of ECMO-implant for every 24 hours until date of weaning or death

    Days on ECMO from ECMO implantation

  2. Weaning from ECMO

    Time frame: From day of ECMO-implant until date of death or weaning

    Weaning from ECMO

  3. ICU length of stay

    Time frame: From day of ICU-admission for every 24 hours until date of death or date of ICU discharge

    ICU length of stay from ECMO implantation

  4. ICU survival

    Time frame: From day of ICU-admission for every 24 hours until date of death or survival at ICU discharge

    ICU survival from ECMO implantation

  5. Hospital survival

    Time frame: From day of hospital admission for every 24 hours until date of death or survival at hospital discharge

    Hospital survival from ECMO implantation

  6. 30-day survival

    Time frame: From day of ECMO-implant for every 24 hours until date of death or survival at 30 days

    30-day survival from ECMO implantation

  7. 90-day survival

    Time frame: From day of ECMO-implant for every 24 hours until date of death or survival at 90 days

    90-day survival from ECMO implantation

Sponsors and collaborators

Lead sponsor

University Medical Centre Ljubljana

Other

Registry information

Official study title

Extracorporeal Membrane Oxygenation in COVID-19, Influenza and ARDS of Other Ethiologies

Important dates

Study start
2016
Primary completion
2022
Study completion
2022
First posted
Apr 29, 2022
Registry last updated
May 5, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.